are actively being pursued, but they have yet to be tested in real experiments to demonstrate their performance.
LCP-SFX.
Recently, we demonstrated that microcrystals can be delivered for SFX experiments more efficiently, with minimal waste, using LCP material as a carrier matrix 13 . LCP is a transparent, gel-like material made of about equal parts of lipids and water 14 . Upon the formation of LCP, lipids self-assemble in a continuous lipid bilayer, mimicking the environment of biological membranes, whereas water segregates into two continuous interpenetrating channels sprawling through the mesophase. Along with a variety of different applications, LCP can be used to stabilize membrane proteins for biochemical or biophysical studies, and to crystallize them from a membrane-like environment 15 . First introduced ~18 years ago, the LCP crystallization method 16 had a relatively slow start; it was not readily embraced by many structural biology groups mostly owing to the difficulties associated with the handling of such viscous and sticky material. Now, after over a decade of technology developments, the use of LCP in the crystallization of challenging proteins has been gaining momentum 15 . To date, this method has contributed over 50 unique membrane protein structures from different families, including receptors, enzymes, transporters and ion channels.
The gel-like consistency of LCP, which is often considered a disadvantage of this material, turned out to be instrumental in its utility for overcoming the problem with high protein consumption required for structure determination by SFX. A special LCP microextrusion injector was designed 13 that allowed the streaming of LCP with embedded microcrystals at very slow flow rates (0.001-0.3 µl/min), which made it possible to fine-tune the flow rate of crystals against the XFEL pulse repetition rate, so that the interval between pulses is just long enough to clear the damaged material out of the beam path and always expose fresh crystals to the new XFEL pulse. An LCP-SFX method was therefore established and successfully used at LCLS (Fig. 1) to collect data on several membrane and soluble protein samples. Structures of two G protein-coupled receptors (GPCRs), the human serotonin receptor 2B (5-HT 2B ) bound to ergotamine 17 and the human smoothened receptor (SMO) bound to cyclopamine 13 , have been published; several other structures are under processing. The LCP-SFX method enables high-resolution structure determination from micron-sized (1-10 µm) crystals at room temperature (~20 °C) with minimal radiation damage. The method eliminates the extensive and tedious crystal optimization process that is otherwise required to obtain sufficiently large crystals for traditional crystallography at synchrotron sources, and it simplifies crystal handling by removing the crystal collection and freezing steps. Here we describe in detail sample preparation protocols for LCP-SFX.
Fixed-target SFX. An alternative method for delivering microcrystals for SFX data collection involves spreading them on a solid support and then rastering with the XFEL beam. This method may further reduce sample consumption for structure determination, but it requires special considerations: the choice of the material for the support, which should be sufficiently rigid but mostly transparent for X-rays; the design of the sample cell, which should keep microcrystals hydrated and also prevent them from being preferentially oriented along the substrate; the rastering pattern, which should allow for fast data acquisition that matches the XFEL pulse repetition rate and ensures efficient sample coverage; and others. The work on implementing serial crystallography with fixed targets both at XFELs and synchrotrons is ongoing [18] [19] [20] [21] ; however, some of the above-mentioned requirements may be difficult to fully satisfy.
Experimental design General considerations.
To use the LCP-SFX approach, researchers must first apply for and be awarded beam time on one of the available hard XFEL sources. Apart from securing access to an XFEL source, LCP-SFX data collection requires the use of an LCP injector 13 and special protocols for sample preparation, which are described below. The primary goal of these protocols is to obtain ~50 µl of LCP that is uniformly filled with microcrystals (<10 µm in size) at a high density. This is typically achieved through a two-stage process. The first stage involves high-throughput crystallization screening in nanoliter volumes using special LCP robots in order to find suitable conditions that lead to a high rate of nucleation and to the formation of a large number of microcrystals. Protocols for setting up high-throughput LCP crystallization trials and crystal detection have been published elsewhere [22] [23] [24] [25] . These protocols are currently being routinely used in many laboratories. Once a suitable crystallization condition is found, the next stage of the process involves scaling up the crystallization volume by ~1,000 times. This scale-up process is not trivial, owing to the gel-like texture of LCP and the slow diffusion of soluble components through it, which leads to transient concentration gradients, the extent and time dependence of which strongly depend on the volume and shape of the LCP crystallization bolus. Here we describe new optimized protocols and other special considerations for achieving samples with a high density of microcrystals in LCP with a total volume of ~50 µl that are suitable for collecting a complete data set by LCP-SFX at an XFEL source. A flowchart of the process is shown in Figure 2 . It begins with reconstitution of the membrane protein of interest in LCP, and then it proceeds to setting up the crystallization experiments in gas-tight syringes. Proteinladen LCP is extruded from one syringe into a precipitant solution in several other syringes as ~400-µm (diameter) string, closely mimicking the geometry used during initial high-throughput crystallization experiments in glass sandwich plates, but in a much larger LCP volume. The syringes are then sealed and incubated at 20 °C to allow the crystals to nucleate and grow. At this stage, the samples can be transported to the beamline inside a Greenbox thermal management system (ThermoSafe Brands) equilibrated at 20 °C. After microcrystals have appeared and reached the desired size, the precipitant solution is discarded and the LCP sample with embedded microcrystals is consolidated into one syringe. The lipid composition of the sample is then adjusted, if necessary (see 'Lipid-phase behavior' below). Finally, the crystal density and size distribution are characterized and optimized, and the sample is transferred into an LCP injector for SFX data collection. To minimize the chance of clogging the injector nozzle, the lipid, protein and precipitant solutions should be pre-filtered, syringes and needles should be thoroughly cleaned, and all manipulations in which the sample is exposed to air should be performed inside a clean-room flow hood.
LCP host lipid selection. Lipids that form LCP, suitable for LCP-SFX applications, are listed in Table 1 . All of these lipids belong to a large class of monounsaturated monoacylglycerols (MAGs). Monoolein (9.9 MAG) has been the most successful lipid used for LCP crystallization to date 26 ; however, several other MAGs have proven to be superior to monoolein in certain cases 27, 28 . LCP samples made of different host lipids have different bilayer thicknesses and water channel diameters, and they respond differently to precipitant solutions, which may affect the stability, diffusion and interaction of the reconstituted membrane proteins. In some cases, doping LCP with phospholipids or cholesterol can improve crystal growth and quality [28] [29] [30] .
Lipid-phase behavior. Most MAG lipids have a very similar temperature-composition phase behavior, as schematically illustrated in Figure 3 . The phase boundary locations, however, are different for each lipid (see the following publications for detailed phased diagrams of several MAGs [31] [32] [33] [34] ). The initial reconstitution of a protein into the lipid bilayer of LCP is performed at room temperature and at close to the maximal hydration capacity of LCP, which is just below the full hydration boundary (marked by an asterisk in Fig. 3) . For most MAGs, this corresponds to the aqueous content of 40-50% (wt/wt; Table 1 ). When a membrane protein sample that has been solubilized in detergent is reconstituted in LCP and then the LCP bolus overlaid with a precipitant solution, these phase boundaries can shift, and in some cases LCP can transform into a different mesophase [35] [36] [37] . It is therefore important to verify that the final mesophase in which microcrystals are grown is an LCP, which is indicated by a gel-like appearance and the lack of birefringence, except for the birefringence that comes from microcrystals.
When LCP, loaded with microcrystals, is extruded into vacuum, rapid evaporative cooling can induce the transition into a crystalline Lc phase (Fig. 3) . This is a common occurrence when monoolein is used as a host lipid because the equilibrium LCP-to-Lc transition temperature for monoolein is 18 °C (ref. 32) , which is only a few degrees below room temperature. The transition to Lc phase may physically damage the crystals, and, moreover, results in excessive powder diffraction from the crystalline lipid that can oversaturate the detector. We have established that this problem can be eliminated by using either 7.9 MAG or 9.7 MAG as a host lipid 13 . When crystal growth requires LCP made of 9.9 MAG, the problem of lipid freezing upon extrusion in vacuum can be Step 1
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Using LCP as a carrier medium for microcrystals of soluble proteins. The LCP-SFX method was developed originally for the structure determination of membrane proteins crystallized in LCP. The method, however, can also be applied to soluble proteins in order to markedly reduce the amount of protein required for structure determination by SFX. It has been shown that small soluble proteins, such as lysozyme or thaumatin, can be crystallized directly in LCP 38, 39 . More generally, microcrystals of a soluble protein, obtained by any crystallization method, can be mixed with an LCP host lipid (Box 1). This method, however, works only when LCP is compatible with the precipitant solution used for crystallization. LCP that is made of monoolein as the host lipid is, in general, the most stable toward the addition of various precipitants used in protein crystallization 35 .
Crystal density and hit rate. One of the most important considerations for successful data collection by LCP-SFX is a high density of crystals, which ensures a high hit rate. The hit rate depends on several parameters including the crystal size, the density of crystals, the injector nozzle diameter and the X-ray beam size. The optimal hit rates are ~30%; lower hit rates require an increasing amount of time for data collection, whereas at higher hit rates the probability of multiple hits increases, making SFX data collection less efficient. Although crystals obtained in a liquid solution can be easily concentrated or diluted, crystals grown in LCP can only be diluted, not concentrated. Therefore, it is imperative to achieve the highest possible density of crystals grown in LCP, which could further be adjusted if necessary. The two-stage protocol described here is designed to first optimize the conditions for achieving the highest crystal density using high-throughput screening with nanoliter sample volumes, and then scaling up the crystallization LCP volume while mimicking closely the conditions and geometry used during the highthroughput screening.
Limitations
The most important limitation of this method is the requirement for maintaining LCP during the crystal growth. Some commonly used precipitants may transform LCP into a lamellar, hexagonal or sponge phase 35 . Although lamellar and hexagonal phases, in general, do not support crystallization and therefore should be avoided, sponge phase can provide a preferred environment for growing crystals of large membrane proteins and complexes 40, 41 . Sponge phase, however, behaves just like a liquid, and thus it is not compatible with the LCP injector and this protocol. Crystals grown in sponge phase have been delivered by a GDVN injector for SFX data collection 10 ; however, as with any other samples that have used the GDVN, samples prepared in the sponge phase suffer from the problem of high crystal consumption at currently available XFELs. In certain cases, it may be possible to lower the concentration of the sponge-inducing component of the precipitant solution (such as PEG400, MPD, Jeffamine M-600 and so on 40 ) after crystal growth and to transform the sponge phase back into LCP; however, such a procedure is not always straightforward and may affect the crystal quality.
Other applications
Although it is developed specifically for data collection at XFELs, the LCP injector may find suitable application at modern synchrotron sources. It has been recently shown that the combination of high-brilliance X-ray beams with fast readout detectors can allow one to outrun the propagation of free radicals, and thus substantially increase the resistance of crystals to radiation dose at room temperature 42 . Continuous shutterless data collection at acquisition rates >10 Hz holds promise for obtaining crystallographic data from medium-sized crystals (10-50 µm) at room temperature. Thus, the use of an LCP injector that produces a 50-to 100-µm-diameter stream at slow flow rates (~0.1 mm/s) may serve as a convenient way to provide a steady supply of fresh crystals for this application. The protocols described in this article are also directly applicable to the sample preparation for such serial crystallography approach at synchrotron sources. EQUIPMENT SETUP Needle stoppers Cut five needles, supplied with 100-µl gas-tight syringes, to ~5-10 mm in length and flatten their tips with pliers; these needle stoppers are to be used for plugging syringes during incubation. Cleaning All syringes, needles and couplers should be thoroughly cleaned with methanol and water, and they should be blow-dried using compressed air. Do not touch any components that may get in contact with lipid or protein with bare hands.  crItIcal It is important that all items are clean before they are used for crystallization setups. All experimental steps, when the sample is exposed to air, should be performed within a clean-air flow hood. 6| Inject ~5 µl of protein-laden LCP sample from syringe no. 2 into syringe no. 3. Control the transferred volume by the scale reading on both syringes (both plungers should move by ~5 µl).  crItIcal step It is important that LCP be extruded as a continuous extended string, fully immersed in the precipitant solution (Fig. 4) .
7| Disconnect syringe no. 3 from the coupler and attach a needle stopper to it.  crItIcal step Watch for the LCP string when disconnecting the syringe from the coupler. Make sure that LCP does not adhere to the coupler needle during the coupler withdrawal.
8|
Use Parafilm strips to seal the needle stopper and the plunger syringe interface (Fig. 4) .  crItIcal step Incomplete sealing may lead to dehydration of the sample, which could affect phase properties of the lipidic mesophase and crystal formation.
9|
Repeat Steps 3-8 to set up crystallization in four additional syringes (nos. 4-7).
10| Place syringe nos. 4-7 in a Ziploc bag, and add a moist fiber-free tissue to maintain a high level of humidity. Seal the Ziploc bag and store it in a 20 °C incubator.  crItIcal step Storing syringes in a Ziploc bag with a moist tissue is essential to prevent dehydration and to improve reproducibility.
Incubation and inspection • tIMInG 1-3 d 11|
Inspect the samples directly inside syringes every 12 h, using a stereo-zoom microscope equipped with cross-polarizers. Microcrystals typically appear within 1-3 d and can be detected as a faint uniform glow or as densely packed bright dots under cross-polarizers (Fig. 4) .
? troublesHootInG  pause poInt Microcrystals grown in syringes can be stored for several days at 20 °C. Avoid large temperature fluctuations (over 2 °C) during sample storage and inspections. Samples in syringes can be transported at this stage to the XFEL source using a Greenbox thermal management system pre equilibrated at 20 °C.
sample consolidation and titration with 7.9 MaG • tIMInG 15 min 12| Take out all the samples from the 20 °C incubator ~1 h before the expected start of LCP-SFX data collection.
13|
Carefully remove Parafilm seals from syringe no. 3.
14|
Replace the needle stopper with a removable needle.
15|
Slowly push the plunger of syringe no. 3, squeezing out the precipitant through the needle.  crItIcal step Push the plunger of syringe no. 3 slowly and carefully. Harsh motion could accidentally squeeze out some LCP along with the precipitant solution, resulting in sample loss.
16|
Stop pushing the plunger when most of the precipitant solution is removed.
17|
Replace the removable needle with a needle stopper.
18| Repeat Steps 13-17 with syringe nos. 4-7.
19| Remove needle stoppers from syringes no. 3 and no. 4 and connect them together using a syringe coupler.
20|
Transfer all of the sample from syringe no. 4 into syringe no. 3.
21|
Repeat Steps 19-20 with syringe nos. 5-7 to consolidate the entire sample in syringe no. 3. Squeeze out as much precipitant as possible.
22|
Transfer ~5 µl of 7.9 MAG into a clean 100-µl syringe (no. 2), and connect syringes no. 3 and no. 2 through a coupler. The use of 7.9 MAG is only required if LCP is extruded in vacuum for LCP-SFX data collection. When performing LCP-SFX experiments at ambient pressure, 9.9 MAG can be used in this step.
23|
Homogenize the sample by moving it through the coupler back-and-forth between syringes. 27| Extrude ~1 µl of the sample onto a glass slide, cover it with a glass coverslip and gently press on the cover to sandwich the sample.
28|
Take images through a high-magnification microscope in bright-field illumination mode and under cross-polarizers. If possible, taking UV fluorescence and SONICC images can help better characterize the sample (Fig. 5) .
29|
Estimate crystal size and density (Fig. 6) . The minimum crystal size is ~1 µm. The minimum crystal density that will work depends on the crystal size, the size of the beam, the diameter of the injector's nozzle and the diffraction strength (see 'Crystal density and hit rate' in the INTRODUCTION for guidelines). If the crystal density is too high ( Fig. 6a; . The estimated total volume of the imaged slice within the depth of focus is 2.6 × 10 −3 µl. For a,c, the total number of crystals is 1,335, the average crystal size is 5.8 µm and the crystal density is 5 × 10 5 crystals per µl. The crystal size and density are too high and will result in multiple hits with any LCP injector nozzle with a diameter from 15 to 50 µm. For an optimal hit rate (~30-40%) with a 30-µm-diameter LCP injector nozzle, the crystals should be diluted ~5 times. For b,d, the total number of crystals is 71, the average crystal size is 4 µm and the crystal density is 2.7 × 10 4 crystals per µl. The crystal size and density are quite low and will result in ~4% hit rate with a 30-µm-diameter LCP injector nozzle. 
33|
Homogenize the contents of the two syringes by moving the sample back-and-forth between syringes ~100 times.
34|
Repeat Steps 26-29 to re evaluate the size and density of microcrystals.
loading the sample in an lcp injector for lcp-sFX data collection • tIMInG 5 min 35| Attach an LCP injector loading needle (1 inch long, gauge 22, point style 3) to syringe no. 2 that contains the final LCP sample homogeneously filled with microcrystals.
36|
Transfer the sample into an LCP injector.
37|
Insert the LCP injector loaded with sample into the sample chamber, start the injector, adjust the LCP flow rate based on the XFEL repetition pulse rate and the detector readout rate, and collect LCP-SFX data. The data collection details used to generate the results shown in this protocol are described in ANTICIPATED RESULTS and in refs. 13, 17 . The details of the data collection will depend on the specific beamline, the hardware and the software used.
? troublesHootInG Troubleshooting advice can be found in table 2. The purified 5-HT 2B /ergotamine complex at a concentration of 20 mg/ml was reconstituted in LCP composed of 10% (wt/wt) cholesterol/90% (wt/wt) monoolein. Initial high-throughput LCP crystallization trials were performed in 96-well glass sandwich plates (Marienfeld) 22 using an NT8-LCP crystallization robot (Formulatrix) and homemade PEG400/salt crystallization screens 44 . Protein-laden LCP was dispensed in 40-nl droplets and overlaid with 800 nl of precipitant solution. Plates were incubated and imaged at 20 °C using an automatic RockImager 1000 incubator/imager (Formulatrix). Initial crystal hits were observed in several conditions. Conditions with magnesium sulfate were optimized further to obtain relatively large crystals (80 µm × 20 µm × 10 µm) for traditional microcrystallography at a synchrotron source ( Fig. 7a,b; ref. 43 ), whereas conditions with magnesium chloride, which reproducibly yielded high-density microcrystals, were used to prepare samples for LCP-SFX ( Fig. 7c,d; ref. 17) .
Crystals optimized for traditional crystallography were collected directly from LCP using MiTeGen micromounts and flash-frozen in liquid nitrogen. Crystallographic data were collected at the 23ID-D beamline of the Advanced Photon Source (APS; Argonne, Illinois, USA) using 10-µm minibeam at a wavelength of 1.0330 Å and a MarMosaic 300 charge-coupled device (CCD) detector. Data from the 17 best crystals collected under cryo-conditions were merged together and used to solve the structure by molecular replacement at 2.7 Å resolution 43 .
Samples for LCP-SFX were prepared in syringes, as outlined in the protocols above, using 90% (wt/wt) monoolein/10% (wt/wt) cholesterol as the LCP host lipid and 100 mM Tris-HCl (pH 8.0), 20-80 mM MgCl 2 , 30% (vol/vol) PEG 400 as precipitant conditions. Seven samples with a total volume of 100 µl were prepared at magnesium chloride concentrations ranging between 20 and 80 mM. Crystallization in syringes was set up in the home laboratory 2 d before the start of the experiment. After an overnight incubation at 20 °C, all samples were transported to LCLS in a Greenbox (Thermosafe Brands) preequilibrated at 20 °C. Before loading the samples into the LCP injector, they were titrated with 7.9 MAG and imaged under visual, UV fluorescence and SONICC microscopes to estimate crystal size (~5 µm) and density ( Fig. 7c,d ; ref. 17) .
LCP-SFX data were collected at the CXI endstation of LCLS (Stanford, California, USA), using 50-fs X-ray pulses (3 × 10 10 photons/pulse) at a repetition rate of 120 Hz and a wavelength of 1.3 Å, focused to a 1.5-µm spot size by Kirkpatrick-Baez mirrors. LCP with randomly dispersed 5-HT 2B /ergotamine microcrystals was extruded through a 20-to 50-µm-diameter nozzle into a vacuum chamber at room temperature and at a constant flow rate of 50-200 nl/min, which was intersected with the XFEL beam. Singe-shot diffraction images (Fig. 7e) were collected using a Cornell-SLAC pixel array detector (CSPAD) located at a distance of 100 mm from the sample. A total of 4,217,508 diffraction patterns were collected within 10 h by using ~0.3 mg of protein. Of these patterns, 152,651 were identified as crystal hits, corresponding to a hit rate of 3.6%. Of these crystal hits, 32,819 patterns (21.5%) were successfully indexed and integrated by CrystFEL 4 . The structure was determined by molecular replacement at 2.8 Å resolution (Fig. 7f) .
Human sMo in complex with cyclopamine SMO belongs to the class of Frizzled GPCRs. It participates in the hedgehog signaling pathway and it is involved in embryonic development and tumor growth. The native agonist for SMO is not known; however, a number of small-molecule agonists and antagonists, including the naturally occurring teratogen cyclopamine 45 , have been recently identified.
For structural studies, the wild-type human SMO was modified by truncating the N-terminal cysteine-rich domain (residues 1-181) and C-terminal residues (at Q555), and by fusing b 562 RIL in place of ICL3 residues 434-440 (ref. 13 ). The engineered construct was expressed in baculovirus-infected Sf9 insect cells, solubilized in DDM/CHS in the presence of cyclopamine, purified by metal affinity chromatography and concentrated to 50 mg/ml.
Initial high-throughput LCP crystallization trials for SMO/cyclopamine were performed as described above for 5-HT 2B / ergotamine. After extensive optimization, relatively large crystals (120 µm × 10 µm × 5 µm) obtained in conditions with ammonium salts were used for data collection at a synchrotron source (Fig. 8a,b) , whereas microcrystals obtained in 100 mM HEPES (pH 7.0), 30% (vol/vol) PEG 400 and 100 mM NaCl were used for LCP-SFX data collection (Fig. 8c,d) . Data collected at APS on the large cryo-cooled SMO/cyclopamine crystals suffered from poor diffraction and high mosaicity, and thus did not yield a structure.
By following the protocols described in this article, we prepared 80 µl of LCP filled with SMO/cyclopamine microcrystals (Fig. 8c,d) . LCP-SFX data were collected at LCLS using the same parameters as those described for 5-HT 2B /ergotamine samples above (Fig. 8e) . A total of 3,510,525 diffraction patterns were collected, of which 274,214 patterns were identified as potential single-crystal diffraction patterns, corresponding to an average hit rate of 7.8%. Autoindexing and structure factor integration of the crystal hits was performed using CrystFEL 4 , resulting in 61,964 indexed images (22.6% indexing success rate). Because of a strong anisotropy, the LCP-SFX data were analyzed using the University of California, Los Angeles (UCLA) anisotropy server (http://services.mbi.ucla.edu/anisoscale/) and truncated at 3.4, 3.2 and 4.0 Å resolution along the three principal axes 13 . The structure was solved by molecular replacement, and it revealed the location of cyclopamine in a narrow and long cavity spanning from the extracellular loop into the transmembrane helical barrel (Fig. 8f) . acknoWleDGMents This work was supported by the US National Institutes of Health grant nos. P50 GM073197 and U54 GM094618. We thank K. Kadyshevskaya for assistance with figure preparation, L. Johansson for comments and A. Walker for assistance with manuscript preparation.
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